ArticleFrontiers in pharmacology2025
Transdermal delivery of traditional Chinese medicine patch vs. NSAIDs patch for alleviating inflammation and relieving pain for early-stage knee osteoarthritis: a retrospective case control study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effects of transdermal delivery of traditional Chinese medicine (TCM) patch for early-stage knee osteoarthritis (EKOA) is unclear. Objective: This study is aimed to compare the therapeutic effects of a type of TCM topical drug-Xiaotong patch with NSAIDs topical drug-flurbiprofen patch to treat EKOA. Methods: This retrospective case control study included 42 EKOA patients from October 2023 to September 2024. Patients were divided into Xiaotong patch group and flurbiprofen patch group. The baseline characteristics, such as demographic and epidemiological information were collected. The main outcome measured was the alteration in Visual Analogue Scale (VAS) score following treatment. The secondary outcomes included inflammatory markers, like cytokine tumor necrosis factor-alpha (TNF-α) and erythrocyte sedimentation rate (ESR). Results: The 42 EKOA patients were divided into two groups averagely. They received the transdermal patch therapy daily for 14 days. The primary outcome-pain assessment based on VAS score showed a prominent decrease in both groups compared with the values before treatment (P < 0.05). There were no significant differences between groups after treatment (P > 0.05). For the secondary outcomes, TNF-α and ESR were included for evaluating the pre- and post-treatment findings. The results also indicated the inflammatory conditions were alleviated by transdermal delivery of drugs from TCM patch or NSAIDs patch. Similarly, the data showed a comparable anti-inflammatory effect between groups (P > 0.05). Conclusion: The TCM transdermal patch exerts a similar effect on the EKOA in the aspects of pain relief and regulating inflammation for a short-term treatment as NSAIDs patch. It may provide an alternative for clinical management of EKOA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.